DEVOTE study initiated of Spinraza for potential greater efficacy when administered at a higher dose than currently approved for Spinal Muscular Atrophy.- Biogen
Biogen announced that the first patient has been treated in the global clinical study, DEVOTE . The study is designed to evaluate the safety, tolerability and potential for… read more.